Sun Pharmaceutical Industries Ltd: Valuation Shift Signals Renewed Price Attractiveness

Valuation Metrics Reflecting Price Adjustment

Sun Pharma’s current price-to-earnings (P/E) ratio stands at 37.39, a figure that, while still elevated, marks a moderation from previous levels that classified the stock as very expensive. This adjustment is significant when viewed against peer companies such as Divi's Laboratories and Torrent Pharmaceuticals, which maintain very expensive valuations with P/E ratios of 74.75 and 77.53 respectively. Cipla and Dr Reddy's Laboratories, meanwhile, trade at comparatively lower P/E ratios of 28.01 and 23.53, indicating a spectrum of valuation within the sector.

The price-to-book value (P/BV) ratio for Sun Pharma is currently 5.58, reinforcing its expensive status but suggesting a more reasonable premium relative to its book value than some peers. Enterprise value to EBITDA (EV/EBITDA) at 24.72 and EV to EBIT at 29.63 further illustrate the company's premium pricing, though these multiples have softened slightly, signalling a potential entry point for investors seeking exposure to a large-cap pharmaceutical leader.

Comparative Sector Analysis and Historical Context

When analysing Sun Pharma’s valuation in the context of its sector, it is clear that the company commands a premium, justified in part by its robust return on capital employed (ROCE) of 26.58% and return on equity (ROE) of 14.92%. These metrics underscore operational efficiency and profitability that exceed many peers, supporting a higher valuation multiple.

Historically, Sun Pharma has delivered strong returns, with a five-year stock return of 182.73% compared to the Sensex’s 45.27% over the same period. Even on a year-to-date basis, the stock has outperformed the benchmark index, returning 12.98% against the Sensex’s negative 9.93%. This outperformance lends credence to the recent upgrade in the company’s Mojo Grade to Buy, reflecting improved investor sentiment and confidence in the company’s growth trajectory.

Mojo Score and Grade Upgrade: Implications for Investors

Sun Pharma’s Mojo Score currently stands at 74.0, a strong indicator of the company’s overall quality and market positioning. The recent upgrade from a Hold to a Buy grade on 8 June 2026 reflects a positive reassessment of the company’s fundamentals and valuation. This upgrade is particularly noteworthy given the stock’s slight day decline of 0.98%, suggesting that the market may be pricing in near-term volatility despite the longer-term bullish outlook.

The valuation grade shift from very expensive to expensive signals a more attractive entry point for investors who had previously been deterred by the stock’s premium multiples. While the PEG ratio remains elevated at 4.14, indicating growth expectations are still priced in, the moderation in P/E and EV/EBITDA multiples suggests a more balanced risk-reward profile.

Dividend Yield and Capital Efficiency

Sun Pharma offers a dividend yield of 0.82%, which, while modest, complements its strong capital efficiency metrics. The company’s ROCE of 26.58% and ROE of 14.92% highlight effective utilisation of capital and shareholder equity, factors that underpin sustainable earnings growth and justify a premium valuation relative to peers.

Investors should note that the company’s enterprise value to capital employed ratio of 7.87 and EV to sales of 7.50 remain elevated but consistent with its large-cap pharmaceutical peers, reflecting the sector’s growth potential and defensive characteristics.

Price Movement and Trading Range

Sun Pharma’s current market price is ₹1,942.95, slightly down from the previous close of ₹1,962.15. The stock has traded within a 52-week range of ₹1,547.25 to ₹1,966.75, indicating that it is near its upper band but has room for upside given its strong fundamentals and sector tailwinds. Today’s intraday range between ₹1,924.50 and ₹1,951.85 reflects typical volatility in a large-cap stock with active institutional participation.

Sector Peer Comparison: Valuation and Growth Expectations

Within the Pharmaceuticals & Biotechnology sector, Sun Pharma’s valuation is positioned between the very expensive valuations of Divi’s Lab and Torrent Pharma and the more moderate multiples of Cipla and Dr Reddy’s Labs. This middle ground suggests that the market recognises Sun Pharma’s leadership and growth prospects but is also factoring in competitive pressures and regulatory risks inherent in the sector.

Divi’s Lab and Torrent Pharma, with P/E ratios above 70 and EV/EBITDA multiples exceeding 40, are priced for aggressive growth, whereas Cipla and Dr Reddy’s Labs offer more value-oriented opportunities. Sun Pharma’s expensive but moderated valuation reflects a blend of growth and stability, appealing to investors seeking a balanced pharmaceutical exposure.

Investment Outlook and Considerations

Sun Pharmaceutical Industries Ltd’s recent valuation adjustment and Mojo Grade upgrade provide a compelling case for investors to reassess the stock’s attractiveness. The company’s strong operational metrics, including a ROCE of 26.58% and ROE of 14.92%, underpin its ability to generate sustainable returns. Coupled with a more reasonable P/E ratio of 37.39 and a price-to-book ratio of 5.58, the stock now offers a more balanced valuation relative to its historical extremes and sector peers.

However, investors should remain mindful of the elevated PEG ratio of 4.14, which indicates that growth expectations remain high and could be susceptible to market or regulatory headwinds. The dividend yield of 0.82% is modest, suggesting that total returns will likely be driven primarily by capital appreciation rather than income generation.

Given the stock’s recent performance—outperforming the Sensex by nearly 23 percentage points year-to-date and delivering a five-year return of 182.73%—Sun Pharma remains a strong contender for inclusion in a diversified pharmaceutical portfolio. The slight day decline of 0.98% may present a tactical buying opportunity for investors looking to capitalise on the company’s robust fundamentals and sector leadership.

Conclusion

Sun Pharmaceutical Industries Ltd’s transition from a very expensive to an expensive valuation grade, alongside a Mojo Grade upgrade to Buy, signals a renewed price attractiveness for investors. The company’s solid financial metrics, competitive positioning within the Pharmaceuticals & Biotechnology sector, and consistent outperformance relative to the Sensex support a positive medium- to long-term investment thesis. While valuation multiples remain elevated, the moderation in key ratios and strong operational returns provide a compelling risk-reward balance for discerning investors.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →